



OPEN ACCESS

EDITED AND REVIEWED BY

Yun Zhang,
Shandong University, China

*CORRESPONDENCE

Kai Huang,
✉ huangkai_hust@126.com

†These authors contributed equally to this work and shared first authorship

RECEIVED 08 June 2023

ACCEPTED 15 June 2023

PUBLISHED 17 August 2023

CITATION

Hu J, Chen R, An J, Wang Y, Liang M and Huang K (2023), Corrigendum: Dauricine attenuates vascular endothelial inflammation through inhibiting NF- κ B pathway.
Front. Pharmacol. 14:1236892.
doi: 10.3389/fphar.2023.1236892

COPYRIGHT

© 2023 Hu, Chen, An, Wang, Liang and Huang. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Dauricine attenuates vascular endothelial inflammation through inhibiting NF- κ B pathway

Ji Hu^{1,2†}, Ru Chen^{1,2†}, Jie An^{1,2,3}, Yilong Wang^{1,2,4}, Minglu Liang^{1,2} and Kai Huang^{1,2,5,6*}

¹Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ²Clinic Center of Human Gene Research, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ³Department of Cardiology, Handan First Hospital, Handan, China, ⁴Department of Cardiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, ⁵Hubei Key Laboratory of Metabolic Abnormalities and Vascular Aging, Huazhong University of Science and Technology, Wuhan, China, ⁶Hubei Clinical Research Center of Metabolic and Cardiovascular Disease, Huazhong University of Science and Technology, Wuhan, China

KEYWORDS

dauricine, endothelial dysfunction, NF- κ B pathway, acute lung injury, inflammation

A Corrigendum on

Dauricine attenuates vascular endothelial inflammation through inhibiting NF- κ B pathway

by Hu J, Chen R, An J, Wang Y, Liang M and Huang K (2021). *Front. Pharmacol.* 12:758962. doi: 10.3389/fphar.2021.758962

In the published article, there was an error regarding the **Affiliation(s)** for “Kai Huang.” In addition to having **Affiliation(s)** 1 and 2, “[5] Hubei Key Laboratory of Metabolic Abnormalities and Vascular Aging, Huazhong University of Science and Technology, Wuhan, China; [6] Hubei Clinical Research Center of Metabolic and Cardiovascular Disease, Huazhong University of Science and Technology, Wuhan, China” should also be included.

In the published article, there was an error in **Figure 4C**, as published. Images of the dauricine-treated (40 μ m + IL-1 β) group in **Figure 4C** were jumbled with the dauricine-treated (20 μ m + IL-1 β) group. The corrected (**Figure 4C**) and its caption “(C) Nuclear translocation of p65, as indicated by the immunofluorescence in HUVECs treated with IL-1 β and dauricine (scale bar: 200 μ m). DAPI was used for nuclear staining (blue). P65 (green) was stained with the Alexa Fluor 488 secondary antibody” appear as follows:

Figure 4 (C) Nuclear translocation of p65 as indicated by the immunofluorescence in HUVECs treated with IL-1 β and dauricine (scale bar :200 μ m). DAPI was used for nucleus staining (blue). P65 (green) was stained with a secondary antibody of Alexa Fluor 488.

In the published article, there was an error in the **Funding** statement. The funding information was missing in the initial version. The correct **Funding** statement appears as follows:

“This study was supported by the National Natural Science Foundation of China (Nos: 81830014 and 91949201).”

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.




FIGURE 4

(C) Nuclear translocation of p65 as indicated by the immunofluorescence in HUVECs treated with IL-1 β and dauricine (scale bar :200 μ m). DAPI was used for nucleus staining (blue). P65 (green) was stained with a secondary antibody of Alexa Fluor 488.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.